Clinical trials to test the new drugs in patients should begin as early as 2015. Existing drugs target faulty versions of a protein called BRAF which drives about half of all melanomas, but while initially very effective, the cancers almost always become resistant to treatment within a year. The new drugs - called panRAF inhibitors - could be effective in patients with melanoma who have developed resistance to BRAF inhibitors. The new study ...
via Medindia Health News More READ
via Medindia Health News More READ
No comments:
Post a Comment